131 related articles for article (PubMed ID: 1394221)
1. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors.
Burrows FJ; Watanabe Y; Thorpe PE
Cancer Res; 1992 Nov; 52(21):5954-62. PubMed ID: 1394221
[TBL] [Abstract][Full Text] [Related]
2. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
3. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
[TBL] [Abstract][Full Text] [Related]
5. [Experimental study of the therapeutic effects of an anti-endothelial cell monoclonal antibody BVE-1 for solid tumor xenograft in nude mice].
Li P; Yuan M; Xia H
Zhonghua Zhong Liu Za Zhi; 1998 Jul; 20(4):280-3. PubMed ID: 10920984
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
Xiang J; Moyana T
Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
[TBL] [Abstract][Full Text] [Related]
7. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex.
Cooke SP; Boxer GM; Lawrence L; Pedley RB; Spencer DI; Begent RH; Chester KA
Cancer Res; 2001 May; 61(9):3653-9. PubMed ID: 11325835
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus induces class II expression in rat heart endothelial cells.
Ustinov JA; Loginov RJ; Bruggeman CA; van der Meide PH; Häyry PJ; Lautenschlager IT
J Heart Lung Transplant; 1993; 12(4):644-51. PubMed ID: 8396436
[TBL] [Abstract][Full Text] [Related]
9. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.
Weber JS; Rosenberg SA
Cancer Res; 1988 Oct; 48(20):5818-24. PubMed ID: 3139284
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor as a marker of tumor endothelium.
Brekken RA; Huang X; King SW; Thorpe PE
Cancer Res; 1998 May; 58(9):1952-9. PubMed ID: 9581838
[TBL] [Abstract][Full Text] [Related]
12. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
[TBL] [Abstract][Full Text] [Related]
13. Penetration and binding of antibodies in experimental human solid tumors grown in mice.
Ong GL; Mattes MJ
Cancer Res; 1989 Aug; 49(15):4264-73. PubMed ID: 2743313
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
15. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
17. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2.
Epstein AL; Khawli LA; Hornick JL; Taylor CR
Cancer Res; 1995 Jun; 55(12):2673-80. PubMed ID: 7780984
[TBL] [Abstract][Full Text] [Related]
18. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
19. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II.
Schwarz RE; Schwarz MA
J Surg Res; 2004 Jul; 120(1):64-72. PubMed ID: 15172191
[TBL] [Abstract][Full Text] [Related]
20. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.
Ward PL; Koeppen HK; Hurteau T; Rowley DA; Schreiber H
Cancer Res; 1990 Jul; 50(13):3851-8. PubMed ID: 2112981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
